Table 2. Series of ⩾15 patients with MPM treated with combination chemotherapy since 1995.
| Agent | First author (year) | No. of patients | Responders | 95% confidence interval (%) | Median survival | |
|---|---|---|---|---|---|---|
| No. | % | |||||
| Doxorubicin-containing combinations | ||||||
| Doxorubicin+cisplatin+mitomycin | Pennucci (1997) | 23 | 5 | 21 | 7 – 42 | 11 |
| Doxorubicin+cisplatin+mitomycin+bleomycin | Breau (1991) | 25 | 11 | 44 | 27 – 63 | na |
| Cisplatin-containing combinations | ||||||
| Cisplatin+DHAC | Samuels (1998) | 29 | 5 | 17 | 5 – 30 | 6.4 |
| Cisplatin+etoposide | Eisenhauer (1988) | 26 | 3 | 12 | 4 – 30 | na |
| Cisplatin+gemcitabine | Byrne (1999) | 21 | 10 | 48 | 26 – 69 | 10.3 |
| Cisplatin+gemcitabine | Novak (2002) | 52 | 17 | 33 | 20 – 46 | 11.2 |
| Cisplatin+gemcitabine | Van Haarst (2000) | 22 | 4 | 15 | na | 10 |
| Cisplatin+Irinotecan | Nakano (1999) | 15 | 4 | 27 | 8 – 55 | 7.1 |
| Cisplatin+mitomycin+vinblastine | Middleton (1998) | 39 | 8 | 20 | na | 6 |
| Cisplatin+pemetrexed (phase I) | Thodtman (1999) | 11 | 5 | 45 | na | na |
| Cisplatin+paclitaxel | Fizazi (2000) | 18 | 1 | 6 | 0 – 24 | 12 |
| Other combinations | ||||||
| Methotrexate+mitoxantrone+mitomycin | Pinto (2001) | 22 | 6 | 32 | 12 – 51 | 13.5 |
| Carboplatin+gemcitabine | Aversa (1998) | 18 | 3 | 16 | na | 8.6 |
| Carboplatin+pemetrexed (phase I) | Hughes (2002) | 25 | 8 | 32 | na | 15 |
| Oxaliplatin+raltitrexed | Fizazi (2000) | 30 | 9 | 30 | 15 – 49 | na |
| Oxaliplatin+vinorelbine | Steele (2000) | 17 | 2 | 12 | na | na |
| Docetaxel+irinotecan | Knuuttila (2000) | 15 | 0 | 0 | 2 – 45 | 8.5 |
na=not applicable.